PolyPid (PYPD) Competitors $3.22 -0.28 (-8.00%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends PYPD vs. BLAC, CLGN, MDAI, COCH, SURG, XAIR, NXGL, STIM, POCI, and IRIXShould you be buying PolyPid stock or one of its competitors? The main competitors of PolyPid include Bellevue Life Sciences Acquisition (BLAC), CollPlant Biotechnologies (CLGN), Spectral AI (MDAI), Envoy Medical (COCH), SurgePays (SURG), Beyond Air (XAIR), NEXGEL (NXGL), Neuronetics (STIM), Precision Optics (POCI), and IRIDEX (IRIX). These companies are all part of the "medical equipment" industry. PolyPid vs. Bellevue Life Sciences Acquisition CollPlant Biotechnologies Spectral AI Envoy Medical SurgePays Beyond Air NEXGEL Neuronetics Precision Optics IRIDEX Bellevue Life Sciences Acquisition (NASDAQ:BLAC) and PolyPid (NASDAQ:PYPD) are both small-cap unclassified companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings, valuation and community ranking. Which has better valuation & earnings, BLAC or PYPD? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBellevue Life Sciences AcquisitionN/AN/AN/AN/AN/APolyPidN/AN/A-$23.86M-$7.81-0.41 Is BLAC or PYPD more profitable? Bellevue Life Sciences Acquisition's return on equity of 0.00% beat PolyPid's return on equity.Company Net Margins Return on Equity Return on Assets Bellevue Life Sciences AcquisitionN/A N/A N/A PolyPid N/A -1,219.71%-134.48% Which has more risk & volatility, BLAC or PYPD? Bellevue Life Sciences Acquisition has a beta of -0.03, meaning that its share price is 103% less volatile than the S&P 500. Comparatively, PolyPid has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Does the media refer more to BLAC or PYPD? In the previous week, PolyPid had 6 more articles in the media than Bellevue Life Sciences Acquisition. MarketBeat recorded 6 mentions for PolyPid and 0 mentions for Bellevue Life Sciences Acquisition. Bellevue Life Sciences Acquisition's average media sentiment score of 0.00 beat PolyPid's score of -0.19 indicating that Bellevue Life Sciences Acquisition is being referred to more favorably in the media. Company Overall Sentiment Bellevue Life Sciences Acquisition Neutral PolyPid Neutral Do analysts prefer BLAC or PYPD? PolyPid has a consensus price target of $12.00, suggesting a potential upside of 272.67%. Given PolyPid's stronger consensus rating and higher possible upside, analysts plainly believe PolyPid is more favorable than Bellevue Life Sciences Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bellevue Life Sciences Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00PolyPid 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor BLAC or PYPD? PolyPid received 28 more outperform votes than Bellevue Life Sciences Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformBellevue Life Sciences AcquisitionN/AN/APolyPidOutperform Votes2877.78% Underperform Votes822.22% Do insiders & institutionals believe in BLAC or PYPD? 55.3% of Bellevue Life Sciences Acquisition shares are owned by institutional investors. Comparatively, 26.5% of PolyPid shares are owned by institutional investors. 33.7% of Bellevue Life Sciences Acquisition shares are owned by company insiders. Comparatively, 24.7% of PolyPid shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryPolyPid beats Bellevue Life Sciences Acquisition on 6 of the 11 factors compared between the two stocks. Ad Brownstone ResearchCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED.Click here to see the details because I believe a lot of people will get rich. Get PolyPid News Delivered to You Automatically Sign up to receive the latest news and ratings for PYPD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PYPD vs. The Competition Export to ExcelMetricPolyPidSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.45M$4.33B$5.01B$9.08BDividend YieldN/A41.45%4.87%4.18%P/E Ratio-0.4125.38135.4317.18Price / SalesN/A45.671,119.53115.67Price / CashN/A43.4640.5837.88Price / Book-2.547.364.754.78Net Income-$23.86M$13.64M$118.50M$225.60M7 Day Performance23.37%-2.76%-1.83%-1.26%1 Month Performance-7.74%0.38%12.27%4.37%1 Year Performance-15.49%44.25%31.72%18.73% PolyPid Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PYPDPolyPid2.3337 of 5 stars$3.22-8.0%$12.00+272.7%-15.5%$15.45MN/A-0.4180Analyst RevisionHigh Trading VolumeBLACBellevue Life Sciences AcquisitionN/A$11.26-0.5%N/A+7.6%$45.50MN/A0.00N/ACLGNCollPlant Biotechnologies2.7297 of 5 stars$3.65-1.1%$12.50+242.5%-35.3%$41.79M$10.96M-2.3870Positive NewsMDAISpectral AI1.9664 of 5 stars$2.00+11.1%$4.50+125.0%-32.5%$37.18M$18.06M-3.1178COCHEnvoy Medical3.2024 of 5 stars$1.82-7.1%$8.00+339.6%-26.7%$36.86M$320,000.000.0034News CoverageSURGSurgePays2.4882 of 5 stars$1.74-2.2%$8.50+388.5%-67.6%$35.08M$137.14M-1.5822XAIRBeyond Air4.1385 of 5 stars$0.48+2.9%$3.67+666.0%-78.9%$34.56M$1.16M-0.3370NXGLNEXGEL0.6527 of 5 stars$5.01+6.4%N/A+125.2%$34.02M$6.73M-8.1210High Trading VolumeSTIMNeuronetics2.9342 of 5 stars$1.10-2.2%$4.67+326.2%-47.5%$33.23M$71.35M-0.89180News CoveragePOCIPrecision OpticsN/A$5.00-2.0%N/A-16.2%$31.75M$19.10M0.0080High Trading VolumeIRIXIRIDEX0.3487 of 5 stars$1.71-0.6%$2.00+17.0%-37.2%$28.45M$48.43M-2.57120Analyst ForecastNews Coverage Related Companies and Tools Related Companies Bellevue Life Sciences Acquisition Alternatives CollPlant Biotechnologies Alternatives Spectral AI Alternatives Envoy Medical Alternatives SurgePays Alternatives Beyond Air Alternatives NEXGEL Alternatives Neuronetics Alternatives Precision Optics Alternatives IRIDEX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PYPD) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PolyPid Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share PolyPid With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PYPD Stock Alerts